ArticleJournal of the American Heart Association2022
Does Adding Adverse Pregnancy Outcomes Improve the Framingham Cardiovascular Risk Score in Women? Data from the Tehran Lipid and Glucose Study.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Life's Essential 8 in Pregnancy and Time to Incident Cardiometabolic Disease Over 7 Years Follow-Up.JAMA network open · 2026Article
- Adverse Pregnancy Outcomes and Long-Term Risk of Chronic Diseases: Evidence from the Findings of the Tehran Lipid and Glucose Study During a Quarter of a Century.International journal of endocrinology and metabolism · 2026Review
- Single-Multiple and Recurrent Pregnancy-Related Complications and Incident Cardiovascular Disease: A Nationwide Data Linkage Study in Wales, UK.Journal of the American Heart Association · 2026Article
- Cardiovascular risk prediction in women: rethinking traditional approaches through precision medicine.Frontiers in global women's health · 2026Review
- The value of pregnancy-related factors in the prediction of cardiovascular disease: a systematic review.International journal of cardiology. Cardiovascular risk and prevention · 2025Review
- Beyond one-size-fits-all: addressing sex differences and promoting inclusive leadership in cardiovascular research and healthcare.BMC medicine · 2025Review
- Association between adverse pregnancy outcomes and awareness of cardiovascular risk factors: A nuMoM2b-HHS secondary analysis.Pregnancy (Hoboken, N.J.) · 2025Article
- Development and validation of a postpartum cardiovascular disease risk prediction model in women incorporating reproductive and pregnancy-related predictors.BMC medicine · 2025Article
- Cardiovascular contributions to dementia: Examining sex differences and female-specific factors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Hypertensive disorders of pregnancy and gestational diabetes mellitus and predicted risk of maternal cardiovascular disease 10-14 years after delivery: A prospective cohort.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Dysglycemia in pregnancy and predicted risk of cardiovascular disease 10-14 years after delivery.Pregnancy (Hoboken, N.J.) · 2025Article
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2025Review
- Pregnancy History at 40 Years of Age as a Marker of Cardiovascular Risk.Journal of the American Heart Association · 2024Article
- 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2024Review
- Article
- Pregnancy complications in last pregnancy and mothers' long-term cardiovascular mortality: does the relation differ from that of complications in first pregnancy? A population-based study.BMC women's health · 2023Article
- Assessment of Cardiovascular Risk in Women: Progress so Far and Progress to Come.International journal of women's health · 2023Review
- Protocol for development and validation of postpartum cardiovascular disease (CVD) risk prediction model incorporating reproductive and pregnancy-related candidate predictors.Diagnostic and prognostic research · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Limited and conflicting evidence is available regarding the predictive value of adding adverse pregnancy outcomes (APOs) to established cardiovascular disease (CVD) risk factors. Hence, the objective of this study was to determine whether adding APOs to the Framingham risk score improves the prediction of CVD events in women. Methods and Results Out of 5413 women who participated in the Tehran Lipid and Glucose Study, 4013 women met the eligibility criteria included for the present study. The exposure and the outcome variables were collected based on the standard protocol. Cox proportional hazard model was used to evaluate the association of APOs and CVDs. The variant of C-statistic for survivals and reclassification of subjects into Framingham risk score categories after adding APOs was reported. Out of the 4013 eligible subjects, a total of 1484 (36.98%) women reported 1 APO, while 395 (9.84%) of the cases reported multiple APOs. Univariate proportional hazard Cox models showed the significant relations between CVD events and APOs. The enhanced model had a higher C-statistic indicating more acceptable discrimination as well as a slight improvement in discrimination (C-statistic differences: 0.0053). Moreover, we observed a greater risk of experiencing a CVD event in women with a history of multiple APOs compared with cases with only 1 APO (1 APO: hazard ratio [HR] = 1.22; 2 APOs: HR; 1.94; ≥3 APOs: HR = 2.48). Conclusions Beyond the established risk factors, re-estimated CVDs risk by adding APOs to the Framingham risk score may improve the accurate risk estimation of CVD. Further observational studies are needed to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.